Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01381471|
Recruitment Status : Completed
First Posted : June 27, 2011
Results First Posted : March 7, 2012
Last Update Posted : March 29, 2012
|Condition or disease||Intervention/treatment|
|Pulmonary Disease, Chronic Obstructive||Drug: fluticasone propionate/salmeterol xinafoate combination|
|Study Type :||Observational|
|Actual Enrollment :||11060 participants|
|Official Title:||Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||May 2010|
|Actual Study Completion Date :||May 2010|
Patients with a diagnosis code of COPD
Drug: fluticasone propionate/salmeterol xinafoate combination
fluticasone propionate/salmeterol xinafoate combination
Other Name: Advair (TM)
- Mean Number of Pharmacy Claims by Participants During the Post-Index Period [ Time Frame: One Year ]The mean number of pharmacy claims incurred by participants during the one-year post-index period was measured.
- Mean Number of Healthcare Encounters Incurred by Participants During the Post-Index Period [ Time Frame: One Year ]The mean number of outpatient office visits, inpatient visits, and emergency department visits incurred by participants during the one-year post-index period was measured.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01381471
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|